An evaluation of dapsone gel 5% in the treatment of acne vulgaris

Bibliography

• Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of western civilization. Arch Dermatol 2002;138:1584-90
   PubMed Web of Science ®Google Scholar
• Stern RS. Dermatologists and office-based care of dermatologic disease in the 21st century. J Invest Dermatol Symp Proc 2004;9:126-30
   PubMedGoogle Scholar
• Haider JC, Shaw JC. Treatment of acne vulgaris. JAMA 2004;292:726-35
   PubMed Web of Science ®Google Scholar
• Leyden JL, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl perioxide alone and a benzoyl/erythromycin combination product. J Cutan Med Surg 2001;5(1):37-42
   PubMed Web of Science ®Google Scholar
• Gollnick H, Cunliffe WJ, Berson D, et al. Managnement of acne; a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49(Suppl 1):S1-S37
   PubMed Web of Science ®Google Scholar
• Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol 1961;73:367-70
   PubMed Web of Science ®Google Scholar
• Kaminsky CA, de Kaminsky AR, Schicci C, et al. Acne treatment with diaminodiphenylsufone. Cutis 1974;13:869-71
   Web of Science ®Google Scholar
• Prendiville JS, Logan RA, Russell-Jones R. A comparison of daponse with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol 1988;13:67-71
   PubMed Web of Science ®Google Scholar
• Zhu IY, Stiller JM. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34
   PubMed Web of Science ®Google Scholar
• Pieters FA, Zuiderma J. The absolute oral bioavailability of dapsone in dogs and humans. Int J Clin Pharmacol Ther Toxicol 1987;25:365-400
   Google Scholar
• Sago J, Hall RP. Dapsone. Dermatol Ther 2002;15:340-51
   Google Scholar
• Pieters FA, Zuidema J. the pharmacokinetics of dapsone after oral administration to healthy volunteers. Br J Clin Pharmacol 1986;22:491-4
   PubMed Web of Science ®Google Scholar
• Zuidema J, Hibers-Modderman ES, Merkus FW. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299-315
   PubMed Web of Science ®Google Scholar
• Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of Dapsone Gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet 2007;46(8):697-712
   PubMed Web of Science ®Google Scholar
• Sanders SW, Zone JJ. The relationship between dapsone dose, serum concentrations and disease severity in dermatitis herpetiformis. Arzneimittelforschung 1986;36:146-9
   PubMed Web of Science ®Google Scholar
• Guo R, Thormann W, Lauterberg B. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. Chin Med J (Engl) 1996;109:933-6
   PubMed Web of Science ®Google Scholar
• Bluhm RE, Adedoyin A, McCaver DG, Branch RA. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of aceylation and hydrozylation of dapsone as risk factors. Clin Pharmacol Ther 1999;65:598-605
   PubMed Web of Science ®Google Scholar
• Crook PR, Hortas C, Roberts EJ, et al. Acetylator phenotype and the effect of dapsone in rheumatoid arthritis. J Rheumatol 1983;10:805-8
   PubMed Web of Science ®Google Scholar
• Queriroz RH, Souza AM, Melchior E, et al. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients. Lepr Rev 1997;68:212-7
   PubMed Web of Science ®Google Scholar
• Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995;40:531-8
   PubMed Web of Science ®Google Scholar
• Cucinell SA, Israili ZH, Dayton PG. Microsomal N-oxidation of dapsone as a cause of methemobglobin formation in human red blood cells. Am J Trop Med Hyg 1972;21:322-31
   PubMed Web of Science ®Google Scholar
• Jollow DJ, Bradshaw TP, McMillan DC, Dapsone-induced hemolytic anemia (review). Drug Metab Rev 1995;27:107-24
   PubMed Web of Science ®Google Scholar
• Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995;26:1461-7
   PubMedGoogle Scholar
• Ganer A, Knobel B, Fryd CH, et al. Dapsone-inducedmethemoglobinermia and hemolysis in the presence of familial hemoglobinopathy Hasharon and familial methemogobin reductase deficiency. Isr J Med Sci 1981;17:703-4
   PubMedGoogle Scholar
• Tingle MD, Mahmud R, Maggs JL, et al. Comparison of the metabolism and toxicity of dapsone in rat, mouse, and man. J Pharmacol Exp Ther 1997;283:817-23
   PubMed Web of Science ®Google Scholar
• Colemane MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-13
   PubMed Web of Science ®Google Scholar
• Schmitdt E, Reimer S, Kruse N, et al. The IL-8 release from human keratinocytes, mediated by anti-bodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 2001;124:157-62
   PubMed Web of Science ®Google Scholar
• Booth SA, Moddy CE, Dahl MV, El AL. Dapsone suppresses intergrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98:130-40
   Google Scholar
• Kazmierowski JA, Ross JE, Peizner DS, et al. Dermatitis herpetiformis:effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity. J Clin Immunol 1984;4:55-65
   PubMed Web of Science ®Google Scholar
• Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear. Skin Pharmacol 1995;8:196-202
   PubMedGoogle Scholar
• Draelos ZD, Carter E, Maloney MJ, et al. Two randomized studies demonstrating the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007;56:439.el-10
   Web of Science ®Google Scholar
• Lucky AW, Maloney MJ, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007;6:981-7
   PubMedGoogle Scholar
• Raimer S, Maloney MJ, Bourcier M, et al. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Curtis 2008;81:171-8
   Google Scholar
• Allergan. A Phase II, randomized study of Aczone™ (dapsone) gel, 5% for papulopustular Rosacea. Available from: www.clinicaltrials.gov [ClinicalTrials.gov Identifier: NCT0024978]. [Accessed 1 September 2008]
   Google Scholar
• Allergan. A Phase III study to compare the safety and efficacy of 5% dapsone topical gel. (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl perozide gel 4%. Available from: www.clinicaltrials.gov [ClinicalTrials.gov Identifier: NCT00151541]. [Accessed 1 September 2008]
   Google Scholar
• Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol 2008;144:1564-70
   PubMed Web of Science ®Google Scholar
• Aczone Topical Gel [package insert]. Irvine, CA: Allergan, Inc.; 2008
   Google Scholar
• Sanders SW, Zone JJ, Foltz RL, et al. Hemolytic anemia induced by dapsone transmitted though breast milk. Ann Intern Med 1982;96:465-6
   PubMed Web of Science ®Google Scholar